Abstract: Objective To investigate the effects of out-hospital extended pharmaceutical intervention on medication compliance and prognosis of myocardial infarction patients after PCI. Methods 160 myocardial infarction patients after percutaneous coronary intervention (PCI) treated in our hospital during Mar 2014 to May 2017 were selected and divided into control group (with 80 patients) and test group (with 80 patients under out-hospital extended pharmaceutical intervention). Prognosis and medication compliance after 1 year discharge between the two groups were compared. Results General data of the two groups had no significant differences between the two groups(P >0.05). LVEDV of control group was higher than test group, LVEF and E/A of control group was lower than test group and the differences were significant (P <0.05). The drug compliance of the test group was higher than that of the control group, the number of compliance was significantly higher than that of the control group, and the number of partial compliance was lower than that of the control group (P <0.05). On the part of prognosis, more patients of control group had cardiovascular adverse events than test group. Among these events, incidences of control group of revascularization and heart failure were significantly higher than test group, which was significantly higher than control group (P<0.05). Conclusion Out-hospital extended pharmaceutical intervention can improve medication compliance and reduce the incidence of cardiac events of myocardial infarction patients after PCI.

Key words: out-hospital extended pharmaceutical intervention, myocardial infarction, medication compliance, prognosis